Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
6.20
-0.09 (-1.43%)
At close: Apr 28, 2026, 4:00 PM EDT
6.16
-0.04 (-0.65%)
Pre-market: Apr 29, 2026, 4:00 AM EDT

Candel Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2019
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2019
Revenue
---0.130.13
Upgrade
Cost of Revenue
---20.3514.59
Upgrade
Gross Profit
----20.22-14.47
Upgrade
Selling, General & Admin
18.4214.614.4114.511.26
Upgrade
Research & Development
29.7618.7323.59--
Upgrade
Operating Expenses
48.1833.333814.511.26
Upgrade
Operating Income
-48.18-33.33-38-34.72-25.73
Upgrade
Interest Expense
-2.12-2.09-2.6-1.71-0.05
Upgrade
Interest & Investment Income
3.921.092.081.22-
Upgrade
Other Non Operating Income (Expenses)
8.29-20.80.9716.42-10.81
Upgrade
EBT Excluding Unusual Items
-38.09-55.14-37.55-18.79-36.59
Upgrade
Asset Writedown
-0.09-0.04-0.39--
Upgrade
Other Unusual Items
----0.46
Upgrade
Pretax Income
-38.18-55.18-37.94-18.79-36.12
Upgrade
Net Income
-38.18-55.18-37.94-18.79-36.12
Upgrade
Net Income to Common
-38.18-55.18-37.94-18.79-36.12
Upgrade
Shares Outstanding (Basic)
5332292919
Upgrade
Shares Outstanding (Diluted)
5332292919
Upgrade
Shares Change (YoY)
67.19%9.47%0.39%52.72%62.49%
Upgrade
EPS (Basic)
-0.72-1.74-1.31-0.65-1.91
Upgrade
EPS (Diluted)
-0.72-1.74-1.31-0.65-1.91
Upgrade
Free Cash Flow
-38.9-27.04-34.7-32.72-24.05
Upgrade
Free Cash Flow Per Share
-0.73-0.85-1.20-1.14-1.27
Upgrade
Operating Margin
----27777.60%-20580.80%
Upgrade
Profit Margin
----15035.20%-28899.20%
Upgrade
Free Cash Flow Margin
----26172.80%-19242.40%
Upgrade
EBITDA
-47.33-32.34-37.04-33.94-25.49
Upgrade
D&A For EBITDA
0.850.990.960.780.23
Upgrade
EBIT
-48.18-33.33-38-34.72-25.73
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.